Greenwich Lifesciences Inc
NASDAQ:GLSI
Intrinsic Value
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. [ Read More ]
The intrinsic value of one
GLSI
stock under the Base Case scenario is
0.54
USD.
Compared to the current market price of 12.62 USD,
Greenwich Lifesciences Inc
is
Overvalued by 96%.
Greenwich Lifesciences Inc's market capitalization is 162.1m USD.
GLSI stock price is 12.62 USD.
GLSI stock (0.54 USD) is 96% less than its price (12.62 USD).
GLSI. Open Relative Valuation
GLSI has upside potential of 191% compared to the average analyst price target.
Open Wall St Estimates
GLSI has negative Free Cash Flow for the last twelve months.
GLSI has negative Operating Income for the last twelve months.
GLSI has negative Net Income for the last twelve months.
GLSI's ROE (Return on Equity) has significantly decreased in the last 3 years from -16% to -89%, and is approaching profitability.
GLSI's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from 336% to 4 048%.
GLSI's ROE (Return on Equity) for the past 12 months is negative and is equal to -89%.
GLSI's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 4 048%.
GLSI has negative three-year average ROE (Return on Equity): -38%. The company is not efficient at transforming stockholders' equity into net income.
GLSI has very high three-year average ROIC (Return on Invested Capital): 2 211%. The company is very efficient at using invested capital to generate operating income.
GLSI's short-term assets (7m USD) exceed its short-term liabilties (294k USD).
GLSI's long-term assets (7m USD) exceed its long-term liabilties (294k USD).
GLSI's D/E (Debt to Equity) is very low and is equal to 0.
GLSI's Altman Z-Score is very high and is equal to 260.93.
Valuation Backtest
Greenwich Lifesciences Inc
Run backtest to discover the historical profit from buying and selling
GLSI
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Greenwich Lifesciences Inc
Balance Sheet Decomposition
Greenwich Lifesciences Inc
| Current Assets | 7m |
| Cash & Short-Term Investments | 7m |
| Non-Current Assets | 5.4k |
| Intangibles | 5.4k |
| Other Non-Current Assets | 10 |
| Current Liabilities | 294.4k |
| Accounts Payable | 256.3k |
| Accrued Liabilities | 38.1k |
Earnings Waterfall
Greenwich Lifesciences Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-9.3m
USD
|
|
Operating Income
|
-9.3m
USD
|
|
Other Expenses
|
436.1k
USD
|
|
Net Income
|
-8.9m
USD
|
Free Cash Flow Analysis
Greenwich Lifesciences Inc
GLSI Profitability Score
Profitability Due Diligence
Greenwich Lifesciences Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
Greenwich Lifesciences Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
GLSI Solvency Score
Solvency Due Diligence
Greenwich Lifesciences Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Greenwich Lifesciences Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GLSI Price Targets Summary
Greenwich Lifesciences Inc
According to Wall Street analysts, the average 1-year price target for
GLSI
is 36.72 USD
with a low forecast of 36.36 USD and a high forecast of 37.8 USD.
Ownership
GLSI Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
GLSI Price
Greenwich Lifesciences Inc
| Average Annual Return | 175.99% |
| Standard Deviation of Annual Returns | 366% |
| Max Drawdown | -90% |
| Market Capitalization | 162.1m USD |
| Shares Outstanding | 12 848 200 |
| Percentage of Shares Shorted | 2.29% |
Company Profile
Greenwich Lifesciences Inc
Country
Industry
Market Cap
Dividend Yield
Description
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company is headquartered in Stafford Texas, Texas and currently employs 3 full-time employees. The company went IPO on 2020-09-25. The firm is developing, GP2, a breast cancer immunotherapy focused on preventing the recurrence of breast cancer following surgery. GP2 is a nine amino acid transmembrane peptide of the human epidermal growth factor receptor two (HER2/neu) protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide specific immunity. Following GP2 immunotherapy, CD8+ cytotoxic T lymphocytes (TCL) recognizes and destroys HER2/neu-expressing cancer cells. The Company’s GP2 treatment is administered through an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. The GM-CSF is available in both liquid and lyophilized forms.
Contact
IPO
Employees
Officers
The intrinsic value of one
GLSI
stock under the Base Case scenario is
0.54
USD.
Compared to the current market price of 12.62 USD,
Greenwich Lifesciences Inc
is
Overvalued by 96%.
You don't have any saved screeners yet
